WO2006007558A3 - Compositions et methodes nouvelles dans le domaine du cancer - Google Patents

Compositions et methodes nouvelles dans le domaine du cancer Download PDF

Info

Publication number
WO2006007558A3
WO2006007558A3 PCT/US2005/023518 US2005023518W WO2006007558A3 WO 2006007558 A3 WO2006007558 A3 WO 2006007558A3 US 2005023518 W US2005023518 W US 2005023518W WO 2006007558 A3 WO2006007558 A3 WO 2006007558A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
present
methods
provides
detection
Prior art date
Application number
PCT/US2005/023518
Other languages
English (en)
Other versions
WO2006007558A2 (fr
Inventor
David W Morris
Marc S Malandro
Albert Lai
Christin Tse
Ali Fattaey
Original Assignee
Sagres Discovery Inc
David W Morris
Marc S Malandro
Albert Lai
Christin Tse
Ali Fattaey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sagres Discovery Inc, David W Morris, Marc S Malandro, Albert Lai, Christin Tse, Ali Fattaey filed Critical Sagres Discovery Inc
Priority to CA002572509A priority Critical patent/CA2572509A1/fr
Priority to AU2005262348A priority patent/AU2005262348A1/en
Priority to JP2007519479A priority patent/JP2009524405A/ja
Priority to EP05769473A priority patent/EP1773382A2/fr
Publication of WO2006007558A2 publication Critical patent/WO2006007558A2/fr
Publication of WO2006007558A3 publication Critical patent/WO2006007558A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne de nouvelles séquences destinées à être utilisées dans la détection, le diagnostic et le traitement de cancers, notamment de lymphomes. L'invention concerne également des séquences polynucléotidiques associées au cancer (CA) dont l'expression est associée au cancer. La présente invention concerne par ailleurs des polypeptides CA associés au cancer qui présentent de nouvelles cibles thérapeutiques dirigées contre le cancer. La présente invention concerne aussi des compositions et des méthodes de diagnostic pour la détection du cancer. La présente invention concerne en outre des anticorps monoclonaux et polyclonaux spécifiques des polypeptides CA. La présente invention concerne enfin des outils de diagnostic ainsi que des compositions thérapeutiques et des méthodes de dépistage, de prévention et de traitement du cancer.
PCT/US2005/023518 2004-07-01 2005-07-01 Compositions et methodes nouvelles dans le domaine du cancer WO2006007558A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002572509A CA2572509A1 (fr) 2004-07-01 2005-07-01 Compositions et methodes nouvelles dans le domaine du cancer
AU2005262348A AU2005262348A1 (en) 2004-07-01 2005-07-01 Novel compositions and methods in cancer
JP2007519479A JP2009524405A (ja) 2004-07-01 2005-07-01 癌における新規な組成物および方法
EP05769473A EP1773382A2 (fr) 2004-07-01 2005-07-01 Compositions et méthodes nouvelles dans le domaine du cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88387804A 2004-07-01 2004-07-01
US10/883,878 2004-07-01

Publications (2)

Publication Number Publication Date
WO2006007558A2 WO2006007558A2 (fr) 2006-01-19
WO2006007558A3 true WO2006007558A3 (fr) 2007-06-14

Family

ID=35784380

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/023518 WO2006007558A2 (fr) 2004-07-01 2005-07-01 Compositions et methodes nouvelles dans le domaine du cancer

Country Status (5)

Country Link
EP (1) EP1773382A2 (fr)
JP (1) JP2009524405A (fr)
AU (1) AU2005262348A1 (fr)
CA (1) CA2572509A1 (fr)
WO (1) WO2006007558A2 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6365577B1 (en) * 1998-10-26 2002-04-02 Avi Biopharma, Inc. p53 antisense agent and method

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6365577B1 (en) * 1998-10-26 2002-04-02 Avi Biopharma, Inc. p53 antisense agent and method

Also Published As

Publication number Publication date
AU2005262348A1 (en) 2006-01-19
WO2006007558A2 (fr) 2006-01-19
JP2009524405A (ja) 2009-07-02
CA2572509A1 (fr) 2006-01-19
EP1773382A2 (fr) 2007-04-18

Similar Documents

Publication Publication Date Title
WO2004074320A8 (fr) Nouvelles cibles therapeutiques pour le cancer
WO2005031001A3 (fr) Nouvelles cibles therapeutiques pour le traitement du cancer
WO2005104810A3 (fr) Nouveaux cibles therapeutiques dans le cancer
WO2004058146A3 (fr) Nouvelles compositions et nouveaux procedes de traitement du cancer
WO2004060304A3 (fr) Compositions et procedes pour la cancerotherapie
WO2005107396A3 (fr) Compositions et procedes nouveaux dans le domaine du cancer
WO2006119365A3 (fr) Compositions et procedes destines au diagnostic et au traitement du cancer
WO2008073312A3 (fr) Épitope de récepteur d'activateur de plasminogène de type urokinase, ses anticorps monoclonaux dérivés et leurs procédés d'utilisation
TW200738748A (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
WO2007016548A3 (fr) Procedes et compositions a base de micro-arn pour le diagnostic, le pronostic et le traitement du cancer du sein
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
WO2006029219A3 (fr) Anticorps monoclonaux humains anti-ctla4 dans le traitement du cancer
WO2006099698A3 (fr) Nouvel anticorps anti-plgf
UA90082C2 (ru) Выделенное моноклональное антитело человека, которое специфически связывается с cd25 человека и ингибирует связывание il-2 с cd25
MX2008009886A (es) Anticuerpos que enlazan par-2.
WO2008053330A3 (fr) Anticorps monoclonaux et fragments de ceux-ci dirigés contre le récepteur de type ii de l'hormone antimüllérienne humaine (amhr-ii)
WO2004067570A3 (fr) Diagnostic et traitement du cancer de la prostate
WO2010017500A3 (fr) Anticorps anti-cancer pancréatique
WO2009019365A3 (fr) Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal
EP1742654A4 (fr) Anticorps anti-lfl2 pour le diagnostic, le pronostic et le traitement d'un cancer
WO2003080808A3 (fr) Nouvelles compositions et nouveaux procedes pour le cancer
WO2007149948A3 (fr) Compositions et procédés de diagnostic et de traitement des tumeurs
WO2006038955A3 (fr) Nouvelles cibles therapeutiques contre le cancer
WO2007033167A3 (fr) Compositions et methodes de detection et de traitement du cancer
UA99602C2 (ru) Антитело, специфически связывающееся с jam-a, способное ингибировать пролиферацию опухолевых клеток

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007519479

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2572509

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005262348

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2005262348

Country of ref document: AU

Date of ref document: 20050701

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2005769473

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005262348

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005769473

Country of ref document: EP